WO2010032248A8 - Multifunctional albumin conjugates - Google Patents
Multifunctional albumin conjugates Download PDFInfo
- Publication number
- WO2010032248A8 WO2010032248A8 PCT/IL2009/000911 IL2009000911W WO2010032248A8 WO 2010032248 A8 WO2010032248 A8 WO 2010032248A8 IL 2009000911 W IL2009000911 W IL 2009000911W WO 2010032248 A8 WO2010032248 A8 WO 2010032248A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multifunctional
- albumin conjugates
- conjugate
- conjugates
- albumin
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 2
- 108010088751 Albumins Proteins 0.000 title abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229930012930 isoflavone derivative Natural products 0.000 abstract 1
- 150000002515 isoflavone derivatives Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to conjugates comprising at least one isoflavone derivative bound to albumin and at least one bioactive moiety including a diagnostic agent or a therapeutic agent, the conjugate being capable of delivering the bioactive moiety into a tumor cell. The invention further relates to the use of said conjugate for the diagnosis and treatment of cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9755308P | 2008-09-17 | 2008-09-17 | |
US61/097,553 | 2008-09-17 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010032248A2 WO2010032248A2 (en) | 2010-03-25 |
WO2010032248A8 true WO2010032248A8 (en) | 2010-06-03 |
WO2010032248A3 WO2010032248A3 (en) | 2010-08-19 |
Family
ID=41786279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2009/000911 WO2010032248A2 (en) | 2008-09-17 | 2009-09-17 | Multifunctional albumin conjugates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010032248A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2798209A1 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
CN103491965A (en) | 2011-02-25 | 2014-01-01 | 奇尼塔公司 | Method and cells for identifying rig-i pathway regulators |
US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
CA3058663A1 (en) | 2017-04-05 | 2018-10-11 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL148825A0 (en) * | 2002-03-21 | 2002-09-12 | Yeda Res & Dev | Derivatives of isoflavones |
-
2009
- 2009-09-17 WO PCT/IL2009/000911 patent/WO2010032248A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010032248A3 (en) | 2010-08-19 |
WO2010032248A2 (en) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006079120A3 (en) | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use | |
EP3281956A3 (en) | Human antibody drug conjugates against tissue factor | |
WO2007150077A8 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2006042146A3 (en) | Multifunctional nanoparticles conjugates and their use | |
WO2010014690A3 (en) | Medical devices for therapeutic agent delivery | |
IL180565A0 (en) | An improved stopcock for administering medicaments into the patient's body | |
WO2010066803A3 (en) | Human antibodies against human tissue factor | |
EP2061503A4 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2009126920A3 (en) | Human serum albumin linkers and conjugates thereof | |
EP1718145A4 (en) | Conjugates for cancer therapy and diagnosis | |
WO2010039861A3 (en) | Dendrimer conjugates | |
WO2009151687A3 (en) | Dendrimer conjugates | |
WO2007018431A3 (en) | Triazole-containing releasable linkers and conjugates comprising the same | |
WO2008008483A3 (en) | Dendrimer based compositions and methods of using the same | |
WO2011038159A3 (en) | Dr5 ligand drug conjugates | |
WO2007105027A8 (en) | Anticancer drugs conjugated to antibody via an enzyme cleavable linker | |
EP2093237A4 (en) | Cancer therapeutic agent comprising anti-hb-egf antibody as active ingredient | |
WO2011008696A3 (en) | Diagnostic methods and compositions for treatment of cancer | |
WO2008031551A3 (en) | Non-neuroendocrine cancer therapy | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
WO2009009203A3 (en) | Dendrimer based compositions and methods of using the same | |
WO2009150284A3 (en) | Apo-a conjugates for the administration of biologically active compounds | |
WO2010046900A3 (en) | Rgd-containing peptidomimetics and uses thereof | |
EP2952210A3 (en) | Compositions comprising saccharide binding moieties and methods for targeted therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09748153 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09748153 Country of ref document: EP Kind code of ref document: A2 |